Epigenetics Giants Merge in Bid to Redefine the Science of Aging

LEXINGTON, KY – April 29, 2026 – In a landmark move poised to reshape the burgeoning longevity industry, Infinite Epigenetics, the parent company of diagnostics leader TruDiagnostic, today announced its acquisition of Tally Health. The deal, described as the largest asset purchase in the history of epigenetic age testing, creates a vertically integrated powerhouse that combines deep scientific research with a direct-to-consumer platform co-founded by famed Harvard geneticist Dr. David Sinclair.

The acquisition unites two of the most prominent names in the field, aiming to build the world's largest private DNA methylation dataset. This fusion of clinical-grade diagnostics and consumer-facing applications signals a major consolidation in the anti-aging market, with the new entity set to accelerate the push of epigenetics from the laboratory into mainstream healthcare.

The Longevity Land Grab

The strategic purchase creates a formidable player in a market experiencing explosive growth. Projections show the global epigenetics sector soaring to over $70 billion by 2034, fueled by a societal shift towards proactive and personalized health. By acquiring Tally Health, Infinite Epigenetics is making a decisive play to capture a significant share of that future.

"We believe epigenetics will underpin the next generation of medical diagnostics, shifting healthcare from reactive treatment to proactive, data-driven prevention," said Dr. Matthew Dawson, who will continue as CEO of Infinite Epigenetics and TruDiagnostic. "Our ambition is to build a category-defining diagnostics platform."

Under the terms of the asset purchase, Tally Health will continue to operate as a standalone consumer brand, preserving its established market presence. Melanie Goldey will remain CEO of Tally Health, while working in tandem with Dr. Dawson to integrate the companies' strengths. The move pits the newly formed entity against a competitive landscape that includes players like Elysium Health and InsideTracker, all vying for dominance in the personalized health space.

The core of the strategy is vertical integration. Infinite Epigenetics brings its CLIA-certified laboratory and the powerful TruAge™ testing platform, which is utilized in over 115 research partnerships with institutions like Harvard and Stanford. Tally Health contributes its accessible consumer brand, a loyal customer base, and exclusively licensed intellectual property from Dr. Sinclair's lab. The synthesis of these assets creates an end-to-end platform—from a cheek swab at home to massive data analysis and personalized supplement recommendations.

The Science of Aging in a Box

At the heart of this merger lies the science of epigenetics—the study of how behaviors and environment can cause changes that affect the way your genes work. Unlike your static DNA sequence, your epigenome is dynamic. DNA methylation is one of the key mechanisms, acting like a series of switches that can turn genes on or off. By analyzing these patterns, companies claim they can determine a person's "biological age," which may be older or younger than their chronological age.

TruDiagnostic has built its reputation on the scientific rigor of its tests, analyzing over 900,000 genetic locations to generate detailed health insights. Tally Health translated this complex science into a user-friendly package: the TallyAge™ Test, an at-home cheek swab that provides a biological age score and an action plan, including proprietary supplements.

The combined company's claim to possess the "world's largest and most diverse private adult DNA methylation datasets" is its most significant asset. In a field driven by data, scale is everything. A larger dataset provides greater statistical power to identify patterns, validate the effectiveness of lifestyle interventions, and train more accurate AI-driven predictive models.

However, some independent scientists urge caution. While epigenetic clocks are a powerful tool for population-level research, some experts question their clinical utility for individuals, suggesting the results can have high variability and may offer more "entertainment value" than actionable medical guidance. In response, TruDiagnostic points to its algorithms, such as the validated DunedinPACE clock, which have been featured in numerous peer-reviewed clinical trials, arguing for their scientific validity.

The Consumer Conundrum: Promise vs. Privacy

For consumers navigating the world of biohacking and longevity, the acquisition presents a mix of promise and potential pitfalls. The promise is one of empowerment. "From day one, Tally Health was built to take the most advanced science of aging and make it actionable for everyday people," said Tally Health CEO Melanie Goldey. The combined company aims to double down on this mission.

Customer experiences, however, have been varied. Users of TruDiagnostic often praise its comprehensive, professional reports, while some Tally Health customers have found its personalized recommendations to be generic or have expressed anxiety over receiving a higher-than-expected biological age. Others report positive results from its supplement regimens, citing improved energy and recovery.

The creation of such a massive epigenetic dataset also raises significant privacy questions. Epigenetic data is uniquely personal and predictive, potentially revealing information about an individual's health predispositions, lifestyle, and even the health of their relatives. Current privacy laws like HIPAA were not explicitly designed to cover this new class of data, creating a potential regulatory gray area. While TruDiagnostic states it adheres to strict HIPAA and ISO-27001 security standards, the aggregation of such sensitive information on a massive scale places a profound responsibility on the company to protect it from breaches and misuse.

The Sinclair Effect: Academia Meets Commerce

Driving much of the consumer interest and scientific credibility behind Tally Health is its co-founder, Dr. David Sinclair. A Professor of Genetics at Harvard Medical School and a global authority on aging, his involvement bridges the gap between academic research and the billion-dollar wellness industry. His philosophy—that genetics account for less than 10% of longevity—empowers consumers by suggesting that over 90% of their healthspan is within their control through daily choices.

"Given that our health is our most important asset, I'm excited to see technologies from my Harvard lab being translated into real-world applications to improve health," Dr. Sinclair stated, endorsing the merger's potential to accelerate that impact.

Dr. Sinclair's continued involvement lends invaluable credibility and marketing power to the new venture, representing a broader trend of esteemed academics commercializing their research. This acquisition is more than just a business transaction; it is a powerful statement about the future of health. It represents the convergence of academic rigor, data-driven technology, and consumer demand, creating a new paradigm where the quest to understand and potentially reverse the aging process is no longer confined to the laboratory.